SUBJECT INDEX: VOLUME 41 (2001)

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parentheses following the page number indicates that the subject entry appeared in a letter to the editor; an "E" in parentheses indicates that the subject was discussed in an editorial; a "/" between numbers indicates on what page the correction for the subject entry appears.

In Volume 41 (2001), Number One (January) contains pages 1-162; Number 2 (February), pages 163-308; Number 3 (March), pages 309-432; Number 4 (April), pages 433-574; Number 5 (May), pages 575-722; Number 6 (June), pages 723-852; Number 7 (July), page 853-974; Number 8 (August); pages 975-1080; Number 9 (September), pages 1081-1178; Number 10 (October), pages 1179-1324; Number 11 (November), pages 1325-1458; and Number 12 (December), pages 1459-1632.

A

AABB response to emergency 1179
AABB standards and quality management 964
ABO blood group
  Bombay phenotype 31
  conversion of group A RBCs to group O 908
  erythrophagocytosis after ABO-mismatched HPC transplant 1463
  expression on platelet gangliosides 504
  IgM antibodies and complement interaction with methoxy-PEG-modified RBCs 1225
  incompatibility and HPC transplant 106
  microplate agglutination method in forward and reverse grouping 627
mismatch in platelet transfusions in heart surgery 790
preparation of IgG MoAb ..... 1(E), 6
  vWF activity levels in ..... 4(E), 56
Acinetobacter johnsonii 862
Acinetobacter lwoffi 862
Accidents
  in selective transfusion protocols 713
  self-reporting of in quality management 964, 1204
ACE inhibitors 136
Activated prothrombin complex concentrate, use in hemophilia patients during hemorrhage ..... 1628(L)
Acute isovolemic hemorrhage 950
Acute lymphoid leukemia, see ALL
Acute myeloid leukemia, see AML
Additive solutions
  experimental for RBC storage 1045, 1586
  for RBCs after thawing ..... 923, 928, 933, 1072(L)
  for storage of platelets 917
Adherence, changes in conversion of group A RBCs to group O 908
Adherence receptors after Hb-based oxygen carrier administration 226
Adhesion molecules and filtration WBC reduction ..... 717(L)
Administrative records of blood use ..... 437(E), 522, 530
Adoptive immunotherapy ..... 111, 117, 853(E), 940
Adult respiratory distress syndrome ..... 312(E), 317
Adverse incident reporting ..... 575(E), 577(E), 579(E), 581, 587, 667, 1204
Affinity column DAT 1258
Agitation of platelets and quality 809
AIDS
  and screening for syphilis ..... 744, 976(E), 1069
  effect on transfusion practice ..... 577(E), 587
Airport, transmission of malaria ..... 301(L)
Algorithm for transfusion in cardiac bypass graft surgery 591, 1193
ALL, WBC-reduced component transfusion and outcome in 873
Allogeneic blood transfusion and postoperative duration of mechanical ventilation 885
Allograft tolerance and blood transfusion ..... 316(E), 416, 419, 988
Alloimmune neonatal neutropenia 615
Alloimmunization to
  HLA antigens ..... 724(E), 762, 766, 771
  PEG-modified RBCs 1225
ALT as screening test for hepatitis ..... 333, 427(L), 751
Altruism and blood donations ..... 165(E), 172
America's Blood Centers response to emergency 1181
American Red Cross response to emergency 1185
Amifostine ..... 168(E), 196
Aminopeptidase P 136
AML 828
Anemia
  and RBC transfusion need and RBC loss from WBC reduction 794
  and predonation Hct level ..... 309(E), 353
  as indicator of underutilization of transfusion ..... 577(E), 587
  in premature neonates and EPO use 406
  induction of increase in bleeding time 977
Ami tribe, HPA and HNA genotypes in 1553
Angiotensin-converting enzyme, see ACE
Annexin V levels in platelet concentrates 243
Antibiotic use after ABO-mismatched platelet transfusion in heart surgery 790
Antibody, general
  development
    after
      ABO-incompatible HPC transplant 106
      Campath chemotherapy ..... 1626(L)
      ceftizoxime 893
      rubella 488
      solid organ transplant 365
    in dogs with bovine Hb-based oxygen carrier 219
    in patients with neoplastic disease 462
    in transgenic mice 1393
    of autoantibodies in pregnancy 1559
    functional assessment of 611
    specificity in Olmsted County, Minnesota 1413
    to HLA antigens ..... 724(E), 762, 766, 771, 1626(L)
    to methoxy-PEG-modified RBCs 1225
    to platelet antigens ..... 724(E), 762, 766, 771, 984
  drug-dependent 893
  granulocyte in IVIG 264
  in
    IVIG that cause TRALI 264
    multiparous donors ..... 312(E), 317
    posttransfusion purpura 633
    refractoriness to platelet transfusion ..... 724(E), 762, 766, 771, 1147
  microplate agglutination method in testing for 627
  optimizing pretransfusion testing and identification of 621
  paraben-dependent 371
  PEG adsorption and detection of autoantibodies and alloantibodies 13
  PEG-modified RBCs 1225
  production
    genetic aspects ..... 1(E), 6
    phage display technique in. ..... 1(E), 6
  WBC, comparison of screening assays for 1147
Antibody, specific
  anti-A 627
  anti-A, B 627
  anti-B 627
  anti-D 106, 1059
  anti-Co3 1273
  anti-Fy^a ..... 365, 970(L)
  anti-Fy^b ..... 970(L)
  anti-HLA-A2 615
  anti-HPA-1a ..... 724(E), 762, 766, 771, 984
  anti-HPA-1b ..... 724(E), 762, 766, 771
  anti-HPA-2b ..... 724(E), 762, 766, 771
  anti-HPA-5a ..... 633, 724(E), 762, 766, 771
  anti-HPA-5b ..... 724(E), 762, 766, 771
  anti-Jk^b 106

anti-K 106, 365
anti-Kp^b 611
anti-Le^b 106
anti-M 106
anti-Nak^a 375
anti-Yop IgA ..... 1331(E), 1365
CTLA-4 462
IgGλ-monotypic cold agglutinin with anti-Pr$_1$ specificity 488
IgG anti-B ..... 1(E), 6
MAR-like 53
paraben-dependent antibody to Rh protein 371
RBC autoantibodies 18, 1559
Anticoagulant to whole blood ratio in autologous blood donation 1606
Antigen, general
conversion of A to O on RBCs 908
detection of D+ cells in a fetomaternal hemorrhage after Rh immune globulin receipt 1059
determination of specificity of 681
expression of C 24
expression on platelet gangliosides 504
Fy phenotype and level of chemokines 378
genotyping to identify 261, 775
microplate agglutination method in testing for 627, 1263
molecular classification of weak D 45
phenotype matching for patients with sickle cell disease 1086
polymorphisms in *FcγRIIIB* 775
potency in Olmsted County, Minnesota 1413
-specific T-cell detection and sorting with MHC-peptide multimers 687
Antigen, specific
A 627, 908
B 627
c 627, 1136, 1408
C 24, 627, 1086
D 627
Dal phenotype ..... 971(L)
DBS 1052
D^c 1136
Do^a 1405
Do^b 1405
e 627
E 627, 1086, 1408
Fy^a ..... 378, 970(L), 1263, 1393
Fy^b ..... 378, 970(L), 1393
HPA-1b 1553
HPA-2b 1553
HPA-4b 1553
HPA-5b 1553
Jk^a 1263
K 627, 1086, 1263
LKE 898
Mit 269
M^v 269
NA1 or HNA-1a 775, 1553
NA2 or HNA-1b 775, 1553
P 898
P^k 898
S^D 269
SH or HNA-1c ..... 847(L), 1553
Antithrombin III 1500
Apheresis
citrate effects during 1165
concurrent, standardized collection of WBC-reduced RBCs, platelets, and plasma 1159
effect on bleeding time 977
efficiency of HPC collection in, by chemotherapy and cytokine regimens 674, 681
iron depletion in collection of 2 units of RBCs 602
intensive and quality of plasma collected 1601
level of platelet growth factors in ..... 1186(E), 1217
reticulated platelets after 1234
safety of collection of platelets ..... 727(E), 756, 857, 1165
serial, collection of granulocytes 390
therapeutic and reactions in 136
Applying transfusion protocols throughout the USA 713
Apolipoprotein A-I 382
Apoptosis
and Fas and Fas ligand ..... 316(E), 416, 988
in WBCs and CTLA-4 antibodies 462
of WBCs in RBCs 67
APT1 mutations 18
Arterial puncture for blood donation 1390
Assay sensitivity and amplification strategy in detection of microchimerism 39
Assessment of virus inactivation 456
Atherosclerosis and *Chlamydia pneumoniae* 1114
Audiovisual, computer-assisted, self-interviewing donor health history 1469
Authors' instructions 157
Autoimmune disease, RBC transfusion and CTLA-4 antibodies in 462
Autoimmune hemolytic anemia 488, 493
Autoimmune lymphoproliferative syndrome 18
Autologous blood donation
immune modulation and transfusion of ..... 316(E), 416, 988
preoperative
decline in ..... 1459(E), 1539
compensatory erythropoiesis in 179
risks of driving to donate blood ..... 152(L)
Autologous blood transfusion, comparison of whole blood or RBCs and FFP 470/851, 988
Automation
in antigen typing of blood 1263
in forward and reverse typing of blood 627
in preparation of cryoprecipitate 232
of detection of bacterial contamination ..... 477, 815, 857, 1331(E), 1351, 1356, 1365, 1486, 1493
of glycerolization and deglycerolization in freezing and thawing RBCs 923, 928, 933
of nucleic acid extraction for screening of single whole-blood units 483
of syphilis screening 744
Aveling apparatus for blood transfusion 968
Aviation Safety Action Partnership 964
A-zyme 908

B

β-thalassemia, development of CTLA-4 antibodies in 462
β-thromboglobulin, release in platelet storage 61
Baboon RBCs released from clot, survival and function of 1384
Babesia microti 440
Bacillus cereus 477, 862, 1493
Bacillus subtilis 477
BaCon, bacterial contamination associated with transfusion reaction study 1486, 1493
Bacteria
and septic transfusion reactions ..... 862, 1075(L)
and WBC reduction 691
antibiotic resistance 1426
contamination in blood components and detection of ..... 74, 287, 427(L), 477, 691, 815, 857, 862, 898, 1075(L), 1114, 1126, 1331(E), 1351, 1356, 1365, 1426, 1486, 1493
fatal reaction due to *Staphylococcus epidermidis* ..... 1075(L), 1493
growth prevention by paraben in LISS 371
in salvaged blood in maxillofacial surgery ..... 1321(L)
incidence of septic reactions after platelet transfusion ..... 857, 1075(L)
model for reporting of contamination with 1486, 1493
protection via RBC phenotype 898
sepsis-type reaction potentiated by Hb-based oxygen carriers 287
Basic science feature ..... 316(E), 416, 687, 988
Baby, evaluation 6 months after cord blood donation ..... 606, 1445(L)
bcr/*abl* cells, quantification of 111
Bellevue Hospital, New York, NY, and first photograph of blood transfusion 968
Beverage, effect on donor temperature 1241

Billing data, validity for use of RBC transfusion data ..... 437(E), 530
Bleeding time
  effect of apheresis on 977
  in vitro test ..... 4(E), 56
Blood
  as source of HPCs ..... 853(E)
  costs and charges ..... 437(E), 522, 530
  credits ..... 165(E), 172, 736
  donation
    allergic reactions in ..... 727(E), 756, 857
    altruism in ..... 165(E), 172
    anemia after ..... 309(E), 353
    apheresis collection of
      2 units of RBCs 602, 1373
      platelets ..... 727(E), 736, 756, 857, 1165
    bacterial contamination in ..... 74, 427(L), 477, 815, 857, 1075(L), 1126, 1331(E), 1351, 1356,1365, 1486, 493
    by
      arterial puncture 1390
      donors in response to emergency 1179, 1181, 1185
      donors of organs 419
      first-time donors ..... 165(E), 172, 360/721, 730, 736, 1179, 1181, 1185
      high-risk donors 1341
      minority donors 360/721, 1179, 1181, 1185
      multiparous donors ..... 312(E), 317, 724(E), 762, 766, 771
      Norwegian donors 1480
      repeat donors 730, 736
      undiagnosed hemochromatosis patients 123
    cataract development in after steroid and G–CSF stimulation for collection of granulocytes 1464
    deferral rates ..... 309(E), 353, 727(E), 756, 857, 1179, 1181, 1185, 1241
    discouragement of by use of incentives 736
    Hct levels before ..... 309(E), 353
    impact of RBC substitutes on 287
    incentives ..... 165(E), 172, 736
    iron depletion in 2-unit RBC apheresis 602
    knowledge of HIV and self-deferral 1341
    of HPCs
      after chemotherapy, with EPO and G–CSF or G–CSF and GM–CSF 674
      bacterial contamination in 1114
      by children ..... 168(E), 201
      CD34+ cell selection in 783, 940, 1008
      comparison of cell separators for 1562
      G–CSF administration schedule ..... 168(E), 190
      spleen enlargement during ..... 168(E), 184
      T-cell depletion 783, 940, 1008
      with/without amifostine and paclitaxel and ifosfamide ..... 168(E), 196
    perception of risk in ..... 1326(E), 1329(E), 1335, 1341, 1459(E), 1539
    preoperative autologous ..... 152(L), 179, 470/851, 988
    recruitment/retention ..... 165(E), 172, 360/721, 736, 1326(E), 1329(E), 1335, 1341
    replacement fee waiver as incentive for blood donation 736
    risk of autologous ..... 152(L), 470/851, 988, 1459(E), 1539
    safety and
      apheresis collection of
        platelets ..... 727(E), 756, 857, 1165
        2 units of RBCs 602, 1373
      G–CSF-stimulated collection of granulocytes 390, 1464
      nerve injury from venipuncture ..... 571(L)
      predonation Hct ..... 309(E), 353
      quality assurance of 964
    screening
      abbreviated donor history for repeat 730
      ALT ..... 333, 427(L), 751
      and long-term survival of transfusion recipients ..... 251, 1153(L)
      anonymous questionnaire for high-risk sexual habits 1480
      anti-HBc to prevent HBV ..... 652, 878, 1081(E), 1093, 1107/1632, 1249
      for antibody to West Nile virus ..... 1320(L)
      for CJD ..... 433(E), 441, 1453(L), 1509
      for CMV 560, 751, 1249
      for EBV 751
      for GBV-C E2 antibody 751
      for HAV 751
      for HBV DNA ..... 329, 643, 652 845(L), 878, 1074(L), 1081(E), 1093, 1107/1632, 1249
      for HCV core antigen ..... 1172(L)
      for HCV RNA ..... 304(L), 333, 427(L), 428(L), 643, 751, 848(L), 1100, 1172(L), 1625(L)
      for HGV RNA 751
      for HIV RNA 483, 643
      for human herpes virus 8 antibody 1120
      for parvovirus B19 ..... 130, 483, 751, 1500
      for syphilis ..... 744, 976(E), 1069
      for TTV 1001, 1130
      history, computer-assisted, audiovisual, self-interviewing 1469
      predonation Hct ..... 309(E), 353
      nucleic acid testing of
        mini-pools ..... 643, 845(L) 1081(E), 1093, 1107/1632, 1249
        single units ..... 483, 845(L)
      temperature 1241
    skin site preparation ..... 427(L), 1075(L) 477, 815, 857, 1331(E), 1351, 1356, 1365
    substitute, see RBC substitute
    transmission of malaria ..... 301(L)
    test seeking in ..... 1326(E), 1329(E), 1335, 1341
    vasovagal syncopal reactions in 1475
    virus infection rates 730
  errors in administration of ..... 575(E), 581, 713, 716(L), 1204
  group collection
    LKE 504, 898
  group systems
    ABO ..... 1(E), 4(E), 6, 31, 56, 106, 504, 627, 790, 908, 1225, 1463
    Co 1273
    Dombrock 1405
    Duffy ..... 365, 378, 970(L), 1263
    Kell 106, 365, 611, 627, 1086, 1263
    Kidd 106, 1263
    Knops 1397
    Lewis 31, 106, 1279
    MNSs 106, 269
    P 898
    Rh ..... 24, 45, 53, 106, 371, 627, 1052 971(L), 1086, 1136, 1408
  safety ..... 165(E), 172, 713, 716(L), 727(E), 736, 756, 857, 964, 1081(E), 1093, 1107/1632, 1249, 1172(L), 1326(E), 1329(E), 1335, 1341, 1459(E), 1469, 1539
  service activity/use of blood ..... 437(E), 522, 530
  smear and erythrophagocytosis by neutrophils ..... 163, 1073(L)
  transfusion safety wall ..... 716(L)
Blood Safety and Availability Advisory Committee and universal WBC reduction ..... 691, 1190(E), 1306, 1310
Blundell, James 968
Bombay phenotype 31
Bone marrow
  as source of HPCs ..... 853(E)
  cryopreservation ..... 579(E), 667
transplant costs ..... 437(E), 522
Books received 432, 1457
Book review 306, 431, 573, 720, 850, 973, 1077, 1078, 1177, 1457, 1630
Bovine Hb-based oxygen carrier 219, 1290
Bowel transplantation 419

Bradykinin metabolism and hypotensive reactions 136
Breast cancer and HPC transplant ..... 168(E), 206, 1577
Buffy coat-derived platelet concentrates ..... 243, 917, 1186(E), 1217
Bystander hemolysis 323

C

Canada, transfusion medicine pioneer in 283
Canale-Smith syndrome 18
Cancer
  adoptive immunotherapy in ..... 853(E)
  Campath chemotherapy and HLA antibody development... 1626(L)
  cells, removal of from HPCs 783
  center, implementation of irradiation program at 1610
  dissemination of tumor cells, RBC transfusion, and CTLA-4 antibodies 462
  fatality due to *Staphylococcus epidermidis* in platelet pool ..... 1075(L)
  gene therapy in ..... 853(E)
  immune modulation of autologous blood ..... 316(E), 416, 988
  recurrence and blood transfusion ..... 316(E), 416, 462, 691, 988
Candida albicans 477
Carboxypeptidases N and M 136
Cash as donor incentive ..... 165(E), 172, 736
Cataracts in granulocyte donors who received G–CSF and steroids 1464
Catechins 456
Catheter gauge and hemolysis of RBCs transfused with external pressure device 799
Cattle, slaughter method and dissemination of brain tissue 1325
Causality assessment 1020
CD61 MoAb for counting platelets in thrombocytopenic patients 1212
CD3+ cell collection 940
CD4+ cell collection 940, 1562
CD8+ cell collection 940
CD19+ cell collection 940
CD34+ cell(s)
  appearance of 975
  collection from cord blood by stem cell filter 1014
  count in blood and collection efficiency 1008
  IL-10 in expansion of 659
  phenotype and engraftment potential of ex vivo expanded umbilical cord blood cells 213
  repopulation of NOD/SCID mice after selection 1014, 1567
  selection system comparison 783, 940, 1008, 1014
CD62+ cells, effect on preparation of topical wound healing products ..... 1186(E), 1217
Ceftizoxime 893
Cell salvage, use in maxillofacial surgery ..... 1321(L)
Cell selection systems 783, 940, 1008
Cell separator(s)
  collection efficiency
    and CD34+ cell count in blood 1008
    and WBC reduction for apheresis platelets 396
    CD34+ cells 783, 940, 1008
    of HPCs, influence of cytokine regimen on 674, 1562
  intermittent-flow or continuous-flow in HPC collection 1562
  MNC collection for adoptive immunotherapy 117, 940
Cellular engineering ..... 853(E)
Central Europe, weak D phenotypes in 45
Centralized transfusion services 713
CFU–E in assessment of virus inactivation 456
CFU–GM, increase in expansion with IL-10 659
Chlamydia pneumoniae 1114
Chelators of metal, use in RBC storage 556
Chemiluminescence-linked universal bacterial ribosomal RNA gene probe detection of bacteria in blood components ..... 477, 815, 857, 1331(E), 1351, 1356, 1365, 1486, 1493
Chemiluminescence test for RBC survival in incompatible transfusion 611
Chemokines and Fy phenotype 378
Chemotherapy mobilization of HPCs ..... 111, 168(E), 196, 674, 681
Chewing gum and donor temperature 1241
Children
  extracorporeal photochemotherapy for GVHD in 1299
  use of G–CSF in ..... 168(E), 201
Children with ALL, use of WBC-reduced components in and outcome 873
Chinese
  Han, Duffy system phenotypes and genotypes in ..... 970(L)
  Hong Kong blood donors and TT virus 1001
Cholesterol screening as blood donation incentive 736
Chromosome 10q abnormality in cord blood donor ..... 606, 1445(L)
Chronic inflammatory disease and *Chlamydia pneumoniae* 1114
Chronic myeloid leukemia 111
Cisplatin, epirubicin, and paclitaxel in HPC collection 674
Citrate levels and toxicity in plateletpheresis ..... 727(E), 756, 857, 1165
CJD ..... 61, 433(E), 441, 449/1079, 1325, 1453(L), 1509
Clearance of donor WBCs in murine model 637
Clostridium perfringens ..... 427(L), 477
Clotting
  of blood sample and release of genomic DNA 276
CMV
  adoptive immunotherapy in ..... 853(E)
  after HPC transplant 783
  and universal WBC reduction ..... 560, 691, 1190(E), 1306, 1310
  DNA screening 1249
Coagulation
  activation of intrinsic cascade 136
  bleeding time ..... 4(E), 56
  factor levels
    after MB treatment ..... 151(L), 1548
    after UVC radiation 456
    in FFP after thawing ..... 570(L)
    in group O FFP ..... 4(E), 56
    in plasma after virus inactivation and filtration WBC reduction 82
  platelet activation of 243
Cold agglutinin disease, after rubella infection 488
Collection efficiency of cell separators 117, 396, 674, 738, 940, 1562
Colloidal resuscitation fluids, effect on neutrophil respiratory burst 1064
Colton blood group system 1273
Communication of
  errors and accidents in transfusion medicine 964, 1204
risk of transfusion ..... 1326(E), 1329(E), 1331(E), 1335, 1341, 1351, 1356, 1365, 1459(E), 1539, 1486, 1493
Community whole-blood donors
  incentives for 736
  infection rates in 730
  response to emergency 1179, 1181, 1185
Comparison of methods of labeling autologous RBCs for survival studies ..... 933, 1072(L)
Complement interaction with PEG-modified RBCs 1225
Complement receptor 1, location of Knops system antigens 1397
Complement system activation after transfusion of autologous whole blood or RBCs and FFP 470/851, 988
Compliance with procedures, direct observation of ..... 575(E), 581
Computer
  -assisted, audiovisual, self-interviewing donor health history 1469
  simulation of erythrocytapheresis in sickle cell disease 256
Concert tickets as incentive for blood donation 736
Contact system activation 136
Continuous-flow cell separator, collection of HPCs 1562
Cord blood
  and gestational age of infant ..... 302(L)
  as source of HPCs ..... 853(E)
  cryopreservation ..... 579(E), 667
  dextran sedimentation of 344, 1014

evaluation of mother and baby after 6 months ..... 606, 1445(L)
expansion of HPCs in ..... 213, 718(L), 853(E), 1567
selection of CD34+ cells from with hydroxyethyl starch 1014
with stem cell collection filter 1014
screening baby for viral markers and history at 6 months after donation ..... 606, 1445(L)
storage, RBC removal, and volume reduction 1014
CPD/ADSOL and survival of autologous RBCs ..... 933, 1072(L)
Coronary artery bypass graft surgery
ABO-mismatched platelet transfusions in 790
bleeding time in 977
predicting need for transfusion in 1193
transfusion and duration of mechanical ventilation after 885
transfusion trigger 591
Coronary artery disease and *Chlamydia pneumoniae* 1114
Corrections 308, 721, 851, 1079, 1632
Corynebacterium species 477
Cost of
ABO-mismatched platelet transfusions in heart surgery 790
blood safety decisions ..... 716(L)
HPC transplant in breast or ovarian cancer 1577
medical interventions triggered by HCV lookback 832
platelet transfusions 1617
RBC transfusion ..... 437(E), 522, 530
universal WBC reduction ..... 1190(E), 1306, 1310
Cost-effectiveness analysis, effect of survival of transfusion recipients ..... 251, 1173(L)
Coumadin, reversal of effects by FFP 3 days after thawing ..... 570(L)
Council of Europe recommendation for
RBC units 1159
universal WBC reduction 1030
C-reactive protein in diagnosis of CJD 1509
^{51}Cr double-label for RBC survival studies ..... 933, 1072(L)
^{51}Cr/^{125}I label for RBC survival studies ..... 933, 1072(L)
^{51}Cr/^{99m}Tc label for RBC survival studies ..... 933, 1072(L)
Cryoprecipitate
preparation
from MB-treated plasma ..... 151(L), 1548
with automated temperature cycling instrument 232
-reduced plasma 840
Cryopreservation of HPCs ..... 579(E), 667
CTLA-4 antibodies 462
Culex mosquito vector for West Nile virus ..... 1320(L)
Culture detection of bacteria in blood ..... 477, 815, 857, 1331(E), 1351, 1356, 1365, 1486, 1493
Cyclophosphamide and G–CSF in collection of HPCs 681
Cys 16 and expression of C 24
Cytokine combinations
effect on efficiency of collection of HPCs 674
for expansion of HPCs ..... 659, 718(L), 1567
Cytokine response after transfusion of salvaged blood in maxillofacial surgery ..... 1321(L)

D

Dal, partial D phenotype ..... 971(L)
DAT
comparison of assays in 1258
in autoimmune lymphoproliferative syndrome 18
Data, administrative for blood use by service ..... 437(E), 522, 530
Decision tree for causality assessment 1020
Deferral of donors ..... 727(E), 756, 857, 1179, 1181, 1185
Deglycerolization of frozen RBCs, automated 923, 928, 933
Delivery of infant, presence of HPCs in mother after 499
Demographic profile of first-time donors 360/721
Dendritic cells ..... 117, 853(E), 940
Desmopressin 1285
Detailed instructions for authors 157
Determinants of transfusion and septic reactions 862
Devices and instruments as sources of bacterial contamination ..... 477, 815, 857, 1331(E), 1351, 1356, 1365
Dexamethasone and collection of granulocytes 1037
Dextran sedimentation of cord blood 344, 1014
Diabetes ..... 1186(E), 1217
Diabodies ..... 1(E), 6
Diagnosis-related groups and transfusion costs ..... 437(E), 522, 530
Diethylenetriaminopentaacetic acid 556
Dimethylmethylene blue 1154
Dinitrochlorobenzene sensitivity, evaluation of donor WBC function in mice 637
Direct observation for compliance with procedure ..... 575(E), 581
Discard of blood after outdate 1179, 1181, 1185
Disseminated intravascular coagulation ..... 570(L)
Dissociation-enhanced lanthanide fluoroimmunoassay 61
DMSO ..... 579(E), 667
DNA exchange between mother and fetus 1524
DNA, genomic, levels in plasma and serum 276
Dogs, bovine Hb-based oxygen carrier use in 219
Dolichos biflorus lectin agglutination of group A RBCs after conversion to group O 908
Dombrock blood group system 1405
Donath-Landsteiner test ..... 163, 1073(L)
Donation interval after 2-unit RBC apheresis 602
Donor
cell transfusions and allograft tolerance 419
lymphocyte transfusion ..... 853(E), 940
response to emergency 1179, 1181, 1185
retested FFP ..... 1172(L)
2,3 DPG-depleted RBCs and acute isovolemic hemorrhage in rat 950, 1515
Drug adsorption mechanism 893
Duck hepatitis B, inactivation in RBCs 1154
Duffy blood group system ..... 365, 378, 970(L), 1263, 1393

E

Earstick sample for predonation Hct ..... 309(E), 353
EBV
adoptive immunotherapy in ..... 853(E)
screening of donors 751
Economic impact of HCV 308
Economy of platelet transfusions 1617
EDTA and counting WBCs after WBC reduction 102
Education credits as donation incentive 736
Electrolytes in experimental additive solutions for RBC storage 1045, 1586
Emergency, response to by donors 1179, 1181, 1185
Enterobacter agglomerans ..... 1331(E), 1357
Enterobacter aerogenes 1493
Enterobacter amnigenus 862
Enterobacter cloacae ..... 477, 1331(E), 1357, 1493
Enterobacter faecalis 862, 1493
Epiflourescence microscopy for detection of bacteria ..... 477, 815, 857, 1331(E), 1351, 1356, 1365, 1486, 1493
Epigallocatechin gallate 456
Epirubicin and
cisplatin and paclitaxel in HPC collection 674
paclitaxel and G–CSF in collection of HPCs 681
Epitope migration ..... 1(E), 6
Epstein Barr virus, see EBV
EPO
levels after 2-unit RBC apheresis 602
recombinant human, in anemia of prematurity 406
response to with oral or IV iron supplementation 957
use in collection of HPCs after chemotherapy 674
Errors
in blood administration ..... 575(E), 581, 713, 716(L), 1204
in laboratory results and underutilization of transfusion ..... 577(E), 578
in selective transfusion protocols 713
management of 964
Erythrocytapheresis, mathematical modeling and computer simulation in sickle cell disease 256
Erythrophagocytosis ..... 163, 908, 1073(L), 1463
Erythropoiesis, compensatory after autologous donation 179

Erythropoietic response to EPO and oral or IV iron supplementation 957
E-selectin induction assay 940
Escherichia coli ..... 477, 504, 815, 857, 862, 898, 1331(E), 1351, 1356, 1365, 1493
Ethics
of nucleic acid testing ..... 304(L)
when framing message of transfusion risk ..... 1326(E), 1329(E), 1335, 1341
Event tickets as donor incentive ..... 165(E), 172, 736
Exo-a-*N*-acetylgalactosamininidase 908
Expansion
cellular engineering of blood components ..... 853(E)
cytokine combinations in ..... 659, 718(L), 1567
good manufacturing practice in ..... 579(E), 667, 718(L), 964, 1567
in serum-free medium ..... 718(L), 1567
of CD34+ cells and changes in cryobiophysical characteristics ..... 579(E), 667
of CFU–E for assessment of virus inactivation 456
of dendritic cells ..... 853(E), 940
of umbilical cord blood HPCs ..... 213, 718(L), 853(E), 1567
Extracorporeal
circulation, risk in plateletpheresis ..... 727(E), 756, 857
photochemotherapy treatment of GVHD in children 1299

F

Fab display library ..... 1(E), 6
Fab fragment detection in fetomaternal hemorrhage 1059
False-positive results in syphilis screening test 744
Fas and Fas ligand ..... 316(E), 416, 988
Fatality
due to *Staphylococcus epidermidis* in platelets ..... 1075(L)
reported in BaCon Study 1486, 1493
FB5.7, human IgG ABO MoAb ..... 1(E), 6
Fcγ receptor III genotype and expression of
NA1 or HNA-1a 775, 1553
NA2 or HNA-1b 775, 1553
SH or HNA-1c ..... 847(L), 1553
FDA
recommendation on WBC-reduction limit 1030
reporting errors and accidents ..... 575(E), 577(E), 587, 581, 713, 716(L), 964, 1204
reports of bacterial contamination 1486, 1493
fetal cellular and cell-free DNA and prenatal diagnosis 1524
fetal HPCs, persistence in mother after delivery 499
Fetomaternal hemorrhage, quantification of 1059
Fever, ABO-mismatched platelet transfusion in heart surgery 790
FFP
ABO type and coagulation factors ..... 4(E), 56
and RBCs or whole blood in autologous transfusion 470/851, 988
coagulation factors in after thawing ..... 570(L)
donor retested ..... 1172(L)
immune modulation from autologous 988
QC of residual cells in 87
Fibrinogen (FI) levels
after MB treatment ..... 151(L), 1548
after virus inactivation and WBC reduction in plasma 82
in cryoprecipitate prepared with automated temperature-cycling instrument 232
in FFP after thawing ..... 570(L)
Ficoll-hypaque sedimentation of cord blood 344
Filopodia 723
Filtration of cord blood for CD34+ cell selection 1014
Filtration reduction of WBCs
and hypotensive reactions 136
and immune modulation 67
and risk of transmission of HBV and HCV 338
conditions that affect efficiency ..... 300(L), 540
counting WBCs after 93, 102
effect of
filter wettability on efficacy of 540
temperature on efficacy of 540
timing of on efficacy of 540
from blood of patients with sickle cell disease or trait 1192
from whole blood without removal of platelets 534
process control of 102
removal of MB by 82
simplification of process 534
use in plasma after virus inactivation ..... .82
Fingerstick sample for predonation Hct ..... 309(E), 353
First-time donors ..... 165(E), 172, 360/721
FISH, see interphase fluorescence in situ hybridization
FITC-BRAD 3, in quantifying fetomaternal hemorrhage after Rh immune globulin receipt 1059
Fluorescent treponemal antibody adsorption test ..... 744, 976(E), 1069
Flow cytometric lymphocyte indirect immunofluorescence test 1147
Flow cytometry
DAT 1258
determination of RBC survival in autoimmune hemolytic anemia 493
identification of WBC antibodies 1147
QC of
residual cells in plasma 87
WBCs after WBC reduction 93, 102
quantification of D+ cells in fetomaternal hemorrhage 1059
Framing the message of transfusion or donation risk ..... 1326(E), 1329(E), 1335, 1341
France, West Nile antibody in donors in ..... 1320(L)
Freezing, type of and impact on plasma quality 1601
Frozen and thawed RBCs 401, 540, 923, 928, 933
Function of donor WBCs in mice 637
Functional capillary density in hamster window model for infusion of bovine cell-free Hb solution 1290
FV levels after intensive apheresis and deep freezing of plasma 1601
FV levels after treatment of plasma with MB 1548
FVIII
concentrates
inactivation of parvovirus B19 in 456
transmission of HBV and HCV 338
use in hemophilia patients with inhibitors during hemorrhage ..... 1628(L)
vWF content of ..... 153(L)
levels
and ABO blood group ..... 4(E), 56
in cryoprecipitate prepared with automated temperature-cycling instrument 232
in FFP after thawing ..... 570(L)
in plasma after
intensive apheresis and deep freezing of plasma 1601
MB treatment ..... 151(L), 1548
virus inactivation and filtration WBC-reduction 82

G

γδ+ cell collection 940
Gamma radiation and storage of apheresis platelets 236
Gangliosides, expression on platelets 504
GBV-C E2 antibody screening in donors 751
G–CSF
and steroid administration and cataracts in granulocyte donors 1464
in expansion of cord blood HPCs 1567
mobilization of HPCs
after chemotherapy and with EPO or with EPO and GM–CSF 674
administration schedule ..... 168(E), 190
administration to children ..... 168(E), 201
in chronic myeloid leukemia 111
effect of
stem cell factor in ..... 168(E), 206
vascular cell adhesion molecule-1 in ..... 168(E), 206
repeating 1438

spleen enlargement after ..... 168(E), 184
with/without amifostine and paclitaxel and ifosfamide ..... 168(E), 196
with paclitaxel 681
-stimulated collection of granulocytes 390, 1037, 1464
use in recovery after HPC transplant for breast or ovarian cancer 1577
Gel column DAT 1258
Gelatin, effect on neutrophil respiratory burst 1064
Gender and monocyte chemotactic protein-1 level 378
Genes
AQP1 1273
bcr/*abl* 111
FcγRIIIB ..... 775, 847(L)
FUT1 and *FUT2* 31, 1279
HFE 828
RHCE 24
RHD 45
RHD-RhcE(5)-RHD hybrid allele 1052
Gene sequencing in causality assessment 1020
Gene therapy ..... 853(E)
Germ cell tumor and HPC transplant ..... 168(E), 196
German Red Cross Award in Transfusion Medicine 974
Gestational age and collection of cord blood ..... 302(L)
Global Aviation Information Network, example of quality management 964
Glycerol in storage of frozen RBCs 401
Glycerolization of RBCs., automated 92
Glycophorin B, single point mutations and antigen production 269
Glycoproteins, platelet, antibodies to ..... 724(E), 762, 766, 771
GM–CSF and mobilization of HPCs 674
GM–CSF use in recovery after HPC transplant for breast or ovarian cancer 1577
Good manufacturing practice in
cell expansion ..... 579(E), 667, 718(L), 964, 1567
plasma product preparation 1020
topical wound healing products ..... 1186(E), 1217
Government regulations of cellular engineering ..... 853(E)
Gram's stain detection of bacterial contamination ..... 477, 815, 857, 1331(E), 1351, 1356, 1365, 1486, 1493
Granuloctye
antibody in TRALI 1421
test and frozen granulocytes 1268
in IVIG 264
in plasma from multiparous donors ..... 312(E), 317
antigen genotyping ..... 775, 847(L)
collection after
G–CSF stimulation 390, 1037, 1464
G–CSF plus dexamethasone stimulation 390, 1037
G–CSF and steroids, cataracts in donors 1464
frozen-stored in tests for antibody detection 1268
toxicity of stimulation regimens 1037
transfusion for infection in neutropenic patients 390
Greece, northwestern, screening for HBV 652
Guanidine hydrochloride 382
GVHD
and HPC transplantation 419, 1299
and solid organ transplantation 419
extracorporeal photochemotherapy treatment 1299
gene therapy in ..... 853(E)
prevention by
gamma radiation of apheresis platelets 236
irradiation of frozen and thawed RBCs 540
Gum chewing, effect on donor temperature 1241

H

H, *h*, and H transferase 31
Hamster window model 1290
Hb
level
as guide for phlebotomy in hemochromatosis 819
as indicator of underutilization of transfusion ..... 577(E), 587
in G–CSF collection of granulocytes 390
in plasma of autologous blood, anticoagulant-to blood ratio 1606
liposome-encapsulated 287
minimum level for donation ..... 309(E), 353
Hb-based oxygen carrier
bovine, use in dogs 219
bovine, use in hamster window model 1290
development of for use in humans 287
neutrophil activation by 226
HbS levels, prediction by mathematical model and computer simulation 256
HAV
inactivation of 456
RNA testing 483
screening of donors for 751
HBV
anti-HBc and anti-HBe screening for ..... 652, 1081(E), 1093, 1107, 1249
DNA testing ..... 329, 483, 643, 652, 845(L), 878, 1074(L), 1081(E), 1093, 1107/1632, 1249
infection in northwestern Greece 652
infection rates in different types of donors 730
infectivity of HBV DNA-positive blood 329
screening babies at 6 months after cord blood donation ..... 606, 1445(L)
transmission in hemophilia patients 338
Hct
and RBC production in preoperative autologous donation 179
level for transfusion in coronary artery bypass graft surgery 591, 1193
predonation sampling method ..... 309(E), 353
HCV
ALT as screening test for ..... 333, 427(L), 751
core antigen testing ..... 1172(L)
economic impact of posttransfusion 308
genotyping error ..... 428(L)
infection rates in different types of donors 730
lookback, health and economic consequences of medical interventions triggered by 832
RNA testing ..... 304(L), 308, 333, 427(L), 428(L), 483, 751, 845(L), 848(L), 1100, 1172(L), 1625(L)
screening babies for 6 months after cord blood donation ..... 606, 1445(L)
testing of donors in
Poland ..... 304(L)
Portugal ..... 848(L)
transmission by carrier ..... 333, 427(L)
transmission in hemophilia patients 338
HDN ..... 4(E), 56, 269, 1273
Health care costs ..... 308, 437(E), 522, 530, 832
Health of patients with posttransfusion HCV after HCV lookback-triggered medical interventions 832
Heart surgery, ABO-mismatched platelet transfusion in 790
Heart transplantation ..... 365, 419, 437(E), 522,
Heart/lung transplantation 419
Hemagglutination of group A RBCs after conversion to group O 908
Hemochromatosis 123, 819, 828
Hemodilution, response to bovine cell-free Hb solution after in hamster window model 1290
Hemodilution, use in maxillofacial surgery ..... 1321(L)
Hemolytic anemia
after rubella infection 488
erythrophagocytosis by monocytes in ..... 163, 1073(L)
immune due to ceftizoxime 893
Hemolysis
immune in conversion of group A RBCs to group O 908
in RBC storage in experimental additive solution 1045, 1586
in RBC transfusion with external pressure 799
Hemophilia
risk of HBV and HCV in 338

treatment of hemorrhage in patients with inhibitors ..... 1628(L)
TT virus genotype in 1130
Hemorrhage, oxygen reserve, and prophylactic RBC transfusion in rats 950, 1515
Hemorrhage, treatment of in patients with inhibitors ..... 1628(L)
Hemostasis and ABO type ..... 4(E), 56
HFE mutations and iron overload in AML patients 828
HGV testing of donors 751
Histocompatiblity and donor WBC clearance in mice 637
History
donor
abbreviated for repeat donations 730
computer-assisted, audiovisual, self-interviewing health history 1469
first photograph of transfusion in USA 968
of syphilis transmission ..... 976(E), 1069
of transfusion medicine in Canada 283
HIV
donor's knowledge of transmission and perceived risk of HIV from donation or transfusion ..... 1326(E), 1329(E), 1335, 1341
and self-deferral 1341
infections rates in different types of donors 730
RBC transfusion needs in anemia in, effect of WBC reduction of RBCs on 794
risk of acquiring from blood donation ..... 1326(E), 1329(E), 1335, 1341
RNA testing ..... 483, 643, 845(L)
screening babies for 6 months after cord blood donation... ..... 606, 1445(L)
HL60 cells, study of WBC-reduction mechanisms ..... 717(L)
HLA
antibodies
after Campath chemotherapy ..... 1626(L)
and hyperhemolysis 323
and refractoriness to platelet transfusion ..... 724(E), 762, 766, 771, 984, 1147
and WBC reduction ..... 691, 1190(E), 1306, 1310
class II, and TRALI 1244
detection by various assays ..... 1626(L)
in alloimmune neonatal neutropenia 615
in autologous transfusion 988
in TRALI ..... 312(E), 317, 1244, 1421
repeat typing of cord blood donors at 6-month follow-up ..... 606, 1445(L)
soluble, class I molecules and immune modulation ..... 316(E), 416, 988
HNA
HNA-1a or NA1 ..... 775, 1553
NHA-1b or NA2 ..... 775, 1553
HNA-1c or SH ..... 847(L), 1553
Hospital
blood service and use of transfusion ..... 437(E), 522, 530
stay in and ABO-mismatched platelet transfusions 790
Hoxworth Quality Donor Service 1469
HPA
anti-HPA-1a ..... 724(E), 762, 766, 771, 984
anti-5a in posttransfusion purpura 633
anti-5b 762, 766
antibodies to in refractoriness to platelet transfusion ..... 724(E), 762, 766, 771, 984
genotyping of for prediction of HNA phenotypes in Taiwanese 1553
HPC
collection
after chemotherapy, by using EPO and G–CSF or G–CSF and GM–CSF 674
Chlamydia pneumoniae in 1114
CD34+ cell selection in 783, 940, 1008
comparison of cell separators in 1562
G–CSF administration schedule ..... 168(E), 190
IL-8 in ..... 168(E), 206
in children ..... 168(E), 201
repeating mobilization and collection of 1438
platelet-secreted mediators in 1431
spleen enlargement ..... 168(E), 184
stem cell factor in ..... 168(E), 206, 1567
T-cell depletion in 783
with cyclophosphamide or epirubicin and paclitaxel and G–CSF 681
with G–CSF with/without amifostine in ..... 168(E), 196
vascular cell adhesion molecule-1 in ..... 168(E), 206
cryopreservation ..... 579(E), 667
expansion ..... 213, 659, 718(L), 1567
fetal, in maternal circulation 499, 1524
storage in –80°C mechanical freezer ..... 579(E), 667
transplantation
ABO-incompatible 106
and allograft tolerance 419
and microchimerism 39, 419
breast cancer ..... 168(E), 206, 1577
CMV after 783
erythrophagocytosis after ABO-mismatched 1463
germ cell tumor ..... 168(E), 206
GVHD in 419, 1299
in chronic myeloid leukemia 111
multiple myeloma ..... 168(E), 206
ovarian cancer 1577
patient age and antibody development 106
reactions during infusion ..... 579(E), 667
HTLV infection rates in types of donors 730
Human Genome Project ..... 316(E)
Human herpes virus 8 antibody prevalence 1120
Human neutrophil antigens, see HNA
Human platelet antigens, see HPA
Human serum albumin ..... 579(E), 667
Hydrophilic polyvinylidene fluoride filter plates 483
Hydroxyethyl starch
effect on neutrophil respiratory burst 1064
HPC cryoprotectant ..... 579(E), 667
sedimentation of cord blood cells 344, 1014
Hyperhemolysis in sickle cell disease 323
Hypertensive effects of Hb-based oxygen carriers 287
Hypotensive transfusion reactions 136

I

Ifosfamide, in HPC collection ..... 168(E), 196
IgG levels in plasma after intensive apheresis and deep freezing of plasma 1601
IgG levels in transfused neonates ..... 154(L)
IgM antibodies in refractoriness to platelet transfusion 1147
IL-1
and TRALI ..... 312(E), 317
receptor antagonist in RBCs 67
IL-3, use in cell expansion 659
IL-6
after transfusion of autologous whole blood or RBCs and FFP 470/851, 988
in diagnosis of CJD 1509
in expansion of cord blood HPCs 1567
role in TRALI ..... 312(E), 317
IL-8
in HPC mobilization ..... 168(E), 206
role in TRALI ..... 312(E), 317
IL-10
in expansion and increase in CFU–GM 659
levels in RBCs 67
Immune complex(es)
and refractoriness to platelet transfusion 1147
mechanism 893
Immune modulation
after autologous whole blood or RBC and FFP transfusion 470/851, 988
after RBC transfusion 67
and development of CTLA-4 antibodies 462
Fas and Fas ligand ..... 316(E), 416, 988

in HPC transplantation ... 106
in very-low-birthweight infants ... 154(L)
WBC reduction and ... 691, 873
Immune reconstitution, after CD34+ cells
election of HPCs ... 783
Immune response
after transfusion of autologous whole blood
or RBCs and FFP ... 470/851, 988
during chemotherapy ... 1075(L)
in patients with neoplastic disease ... 462
in very-low-birthweight infants ... 154(L)
to PEG-modified RBCs ... 1225
Immune tolerance ... 1(E), 6
Immunologic changes in group A RBCs in
conversion to group O RBCs ... 908
Immunopathology
of bovine Hb-based oxygen carrier in dogs ... 219
of human Hb-based oxygen carrier ... 287
Implementation of blood irradiation program
in cancer center ... 1610
Incentives for blood donation ... 165(E), 172, 736
Indirect antiglobulin test ... 621
Infection
and WBC reduction ... 691
postoperative and blood transfusion ... 316(E), 416, 988
rates in different types of donors ... 730
treatment with granulocytes ... 390
Infectivity assay for assessment of virus inactivation ... 456
Inflammatory response and transfusion ... 885, 1321(L)
Information sharing of errors and accidents in
transfusion medicine ... 964, 1204
Informed consent
and nucleic acid testing ... 304(L)
and risk perception ... 1326(E), 1329(E), 1335, 1341
discussion of preoperative autologous
blood donation ... 1459(E), 1539
Inhibitors in hemophilia patients and treatment
of hemorrhage ... 628(L)
Injuries from vasovagal syncopal reactions after
blood donation ... 1475
Insulin-like growth factor I ... 1186(E), 1217
Instructions for authors ... 157
Instruments and devices as source of bacterial
contamination ... 477, 815, 857, 1331(E), 1351, 1356, 1365, 1486, 1493
Insulin-like growth factor I ... 1186(E), 1217
Intensive care stay, ABO-mismatched platelet
transfusion in heart surgery ... 790
Intermittent-flow cell separator, collection of HPCs ... 1562
Interphase fluorescence in situ hybridization (FISH) ... 111
Interval between donations and RBC production
in preoperative autologous donation ... 179, 1459(E), 1539
Intravenous immune globulin, lack of TT virus transmission ... 1505
Ionized calcium level in plateletpheresis ... 1165
Ionized magnesium level in plateletpheresis ... 1165
Iron
depletion in 2-unit RBC apheresis ... 602
level in undiagnosed hemochromatosis
patients who donate blood ... 123
oral or IV in erythropoietic response to EPO ... 957
overload in patients with AML ... 828
prevention of overload in hemochromatosis ... 819
supplementation in
orthopedic surgery and EPO administration ... 957
preoperative autologous donation ... 179
Irradiation
effect on donor WBC clearance in mice ... 637
implementation of program for ... 1610
of frozen and thawed RBCs ... 540
IVIG
lack of TT virus transmission in ... 1505
granulocyte antibody in and TRALI ... 264
use during hyperhemolysis ... 323

J

Jamaican Cohort Study of Sickle Cell Disease ... 596
Jean Julliard Prize ... 1458
Jehovah's Witnessess ... 577(E), 587

K

Kallikrein-kinin system ... 136
Kell blood group system ... 106, 611, 627, 1086, 1263
Kidd blood group system ... 106, 1263
Kidney transplantation ... 365, 419
Kinetics of fetal cellular and cell-free DNA in
maternal circulation and prenatal diagnosis ... 1524
Kinetics of TPO uptake in platelet transfusion ... 517
Kinins ... 136
Klebsiella oxytoca ... 477, 862, 1331(E), 1357
Klebsiella pneumoniae ... 862, 1357
Knops blood group system ... 1397

L

Labels for RBC survival studies ... 933, 1072(L)
Laboratory result errors and underutilization of
transfusion ... 577(E), 578
Lactate production, effect on preparation of
topical wound-healing products ... 1186(E), 1217
Lactic acid production in unagitated platelets ... 809
Lamellae ... 723
Leukapheresis
collection, efficiency of systems ... 783, 940, 1008
component detection of bcr/*abl* cells in ... 111
Leukemia, transfusion costs of ... 437(E), 522, 530
Leukocyte function antigen 1 ... 300(L)
Lewis blood group system ... 31, 106, 1279
Life expectancy of transfusion recipients
in Sweden ... 251, 1173(L)
with posttransfusion HCV after medical
intervention triggered by lookback ... 832
Lipoprotein, virus inactivation in ... 382
Liposome-encapsulated Hb ... 287
LISS, paraben-dependent antibody to Rh protein ... 371
Liver
disease
as predictor of platelet transfusion need
in neonates ... 803
use of FFP 3 days after thawing ... 570(L)
transplantation ... 365, 419, 437(E), 522
LKE
activity on platelet gangliosides ... 504
role in susceptibility to shiga toxin ... 898
Lookback, HCV, medical interventions triggered by ... 832
Lottery tickets as donation incentive ... 165(E), 172, 736
Lymphocyte
phenotypes in transfused neonates ... 154(L)
subset analysis after WBC reduction ... 1591
transplantation with solid organs ... 365, 419
Lymphocytotoxicity test ... 724(E), 762, 766, 771, 1147
Lymphoid cell recovery after HPC transplant
for breast or ovarian cancer ... 1577

M

Malaria, airport ... 301(L)
Mannitol, addition to additive solution for
11-week storage of RBCs ... 1586
Maternal circulation, fetal HPCs in ... 499, 1524
Mathematical modeling of
erythrocytaphersis for sickle cell disease ... 256
preoperative autologous blood donation ... 1459(E), 1539
Maxillofacial surgery, use of cell salvage in ... 1321(L)
Maximum surgical blood-ordering schedule ... 577(E), 587
MB
cryoprecipitate from plasma treated with ... 151(L), 1548

demand for products treated with 1548
removal by filtration WBC reduction 82
MCV as guide for phlebotomy in hemochromatosis 819
Mechanical ventilation, postoperative 885
Media presentation of risk in transfusion or donation ..... 1326(E), 1329(E), 1335, 1341
Medical Event Reporting System for Transfusion Medicine 964, 1204
Medical interventions triggered by HCV lookback 832
Medical tests as donor incentives ..... 165(E), 172
Melanoma 117
Merchandise discount as donor incentive ..... 165(E), 172
Message framing for transfusion risk ..... 1326(E), 1329(E), 1335, 1341
Meta analysis of
EPO use in anemia of prematurity 406
universal WBC reduction 691
Methods of detection of bacterial contamination in blood components ..... 477, 815, 857, 1331(E), 1351, 1356, 1365, 1486, 1493
Methylene blue, see MB
MHC
complex, in donor WBC clearance in mice 637
peptide multimers 687
Microchimerism 39, 276, 365, 419, 637, 1524
Microplate agglutination in ABO grouping 627
Microvascular response to
bovine cell-free Hb solution 1290
transfusion of stored RBCs in rats 1515
Microvolume fluorimeter 93, 102
Mini-pool nucleic acid testing ..... 483, 643, 845(L) 1081(E), 1093, 1107/1632, 1249
Minority donors 360/721
Misclassification of donor by nucleic acid testing ..... 428(L), 1625(L)
Mitochondrial DNA in detection of donor platelets in recipient 1531
MNCs
collection of with cell separator 117, 940
expansion of ..... 659, 853(E)
in adoptive immunotherapy ..... 117, 853(E), 940
MNSs blood group system 106, 269
MoAb(s)
in identification of
granulocyte antigens 775
partial D phenotype, DAL ..... 971(L)
production ..... 1(E), 6, 1393
Monetary incentive for blood donation ..... 165(E), 172, 736
Monitoring for underutilization of transfusion ..... 577(E), 578
Monoclonal antibody-specific immobilization of platelet antigens assay ..... 724(E), 762, 766, 771
Monocyte activation in conversion of group A RBCs to group O 908
Monocyte chemotactic protein-1 and Fy phenotype 378
Monocyte collection 940
Mosquito and transmission of West Nile virus in France ..... 1320(L)
Mother
evaluation of 6 months after cord blood donation ..... 606, 1445(L)
persistence of fetal HPCs in 499, 1524
Mortality rate after
ABO-mismatched platelet transfusions in heart surgery 790
blood transfusion in Sweden ..... 251, 1173(L)
transfusion of WBC-containing components 691
Mosquito, transmission of malaria to airport mechanic ..... 301(L)
Mpl, platelet receptor for TPO 517
Mucoviscidosis in cord blood donor on follow-up ..... 606, 1445(L)
Multiple myeloma and HPC transplant ..... 168(E), 206
Multiparous donors ..... 312(E), 317, 724(E), 762, 766, 771
Murine model of WBC clearance 637
Myeloid cell recovery after HPC transplant for breast or ovarian cancer 1577

N

Nageotte chamber 87, 93, 102
Near-miss events 1204
Neonates
alloimmune neutropenia and anti-HLA-A2 615
alloimmune thrombocytopenia 375
collection of cord blood and gestational age ..... 302(L)
EPO and anemia in 406
immune response after transfusion ..... 154(L)
predicting platelet transfusion use in 803
RBC transfusion through pressure device 799
use of TPO in 803
Neopterin 470/851, 988
Nerve injury in whole blood donation ..... 571(L)
Neuron-specific endolase 1509
Neutropenia
alloimmune in neonate and anti-HLA-A2 615
granulocyte transfusion in 390
Neutrophil
activation by Hb-based oxygen carriers 226
count in G–CSF-stimulated collection of granulocytes 390
erythrophagocytosis by in paroxysmal cold hemoblobinuria ..... 163, 1073(L)
respiratory burst, effects of resuscitation fluids on 1064
Neutral endopeptidase 24.11 136
NK cell collection 940
NOD/SCID mice, repopulation studies 1014, 1567
Nonsurgical blood loss, anemia and bleeding time in 977
Northwestern Greece, screening for HBV in donors 652
Norwegian blood donors, risk behavior in 1480
Notification of donors with false-positive syphilis test 744
Nucleic acid levels in serum and plasma 276
Nucleic acid testing
automation of nucleic acid extraction 483, 1100
ethics of ..... 304(L)
HBV ..... 329, 483, 643, 652, 845(L), 878, 1074(L), 1081(E), 1093, 1107/1632, 1249
HCV
detection of carrier of ..... 427(L), 333, 1625(L)
erroneous genotyping of ..... 428(L)
health and economic impact of 308
in donors in
Poland ..... 304(L)
Portugal ..... 848(L)
of single units ..... 483, 845(L)
mini-pool testing ..... 643, 845(L), 1081(E), 1093, 1107/1632, 1249
RNA ..... 304(L), 308, 333, 427(L), 428(L), 483, 751, 845(L), 848(L), 1100, 1172(L), 1625(L)
when ALT =120 IU/L 751
HIV-1 ..... 483, 643, 845(L)
mini-pool vs. single-unit ..... 483, 643, 845(L) 1081(E), 1093, 1107/1632, 1249
sample processing 643
TT virus 1505
use in causality assessment of plasma products 1020

O

Olmstead County, Minnesota, RBC antibody specificity and antigen potency in 1413
Open heart surgery, ABO-mismatched platelet transfusion in 790
Operation of blood irradiation program 1610
Opsonic index in transfusion of incompatible RBCs 611
Orientia tsutsugamushi ..... 1454(L)
Orthopedic surgery, iron supplementation with EPO in 957
Oxygen
carrier of Hb
tests in hamster window model 1290
use in dogs 219
-carrying solutions

and neutrophil activation 226
progress in development of 287
consumption in rat intestine after transfusion of stored RBCs 1515
delivery
by bovine cell-free Hb solution in hamster window model 1290
in rats by transfused stored RBCs 1515
extraction level, whole body, as transfusion trigger in cardiac bypass graft surgery 591
levels in TRALI ..... 312(E), 317
reserve, effect of 2,3 DPG-depleted RBCs on in rats 950, 1515
utilization in unagitated platelets 809

P

P blood group system 898
Paclitaxel, HPC collection with cisplatin and epirubicin 674
G–CSF and ifosfamide with/without amifostine ..... 168(E), 196
G–CSF or G–CSF and GM–CSF 681
Paid blood donors ..... 165(E), 172
Pancreas transplantation 365, 419
Paraben-dependent antibody to Rh protein 371
Parathyroid hormone levels in plateletpheresis 1165
Paroxysmal cold hemoglobinuria ..... 163, 1073(L)
Parvovirus B19 ..... 130, 382, 456, 483, 751, 1500
Passenger lymphocyte syndrome 365
Pasteurization to inactivate viruses 382
Patient's perception of risk of transfusion ..... 1326(E), 1329(E), 1335, 1341, 1459(E), 1539
PBPC(s), see HPC(s)
PCR
detection of
bacteria ..... 477, 815, 857, 1331(E), 1351, 1356, 1365
CMV 1249
donor's platelets in recipients 1531
microchimerism 39
parvovirus B19 1500
high-titer screening 1500
quantitative, competitive 111
screening for weak D 45
PEG
adsorption of autoantibodies 13
indirect antiglobulin test 621, 1263
-modified RBCs 1225
Penicillin ..... 976(E), 1069
Perfluorocarbon-based RBC substitutes 287
Perinatal immunohematology practice guidelines 1445
Phage display library and technique ..... 1(E), 6
Pharmacovigilance 1020
Phenylketonuria in cord blood donor on follow-up ..... 606, 1445(L)
Philadelphia translocation 111
Phlebotomy
MCV as guide for in hemochromatosis 819
nerve injury during ..... 571(L)
site preparation 74
therapeutic 123
Plasma
causality assessment in 1020
concentration of cell-free genomic DNA in 276
cryoprecipitate-reduced, in treatment of thrombotic thrombocytopenic purpura 840
donor retested ..... 1172(L)
diagnosis of CJD in 1509
inactivation of CJD agent in ..... 433(E), 441, 449/1079, 1453(L)
multiparous-donor ..... 312(E), 317
parvovirus B19 antibodies in 130
preparation of cryoprecipitate from after treatment with MB ..... 151(L), 1548
PrP^c in and removal of during processing of ..... 61, 433(E), 441, 449/1079, 1453(L)
QC of residual cells in 87
quality after deep freezing and changes in intensity of apheresis 1601
septic reaction risk after ..... 857, 1331(E), 1351, 1356, 1365, 1486, 1493
screening for parvovirus B19 in 1500
standardized apheresis collection of WBC-reduced plasma, with RBCs and platelets 1159
TPO concentration in 517
viral marker screening 643
virus inactivation
and filtration WBC reduction of 82
of parvovirus B19 382
pasteurization 382
virus transmission causality assessment of 1020
pH of experimental additive solutions for RBC storage 1045, 1586
Photochemotherapy, extracorporeal, treatment of GVHD 1299
Photograph, first of blood transfusion 968
Photoinactivation of duck hepatitis B virus 1154
Photoinactivation, preference for products treated with 1548
Plasmids ..... 1(E), 6
Platelet(s)
ABO-mismatched and heart surgery 790
activation
after gamma radiation and storage of apheresis platelets 236
and efficiency of WBC-reduction filters ..... 300(L)
electronmicrograph of 723
in preparation of pooled, buffy coat-derived, WBC-reduced platelets 243
of coagulation system 243
additive solution 917
adhesion immunofluorescence test ..... 724(E), 762, 766, 771
agitation, continuous effect on quality 809
agglutination test ..... 724(E), 762, 766, 771
annexin 5 levels in 243
antibody
anti-Nak^a and neonatal alloimmune thrombocytopenia 375
detection ..... 724(E), 762, 766, 771, 1626(L)
false-positive tests for because of Campath chemotherapy ..... 1626(L)
HPA-5a and
posttransfusion purpura 633
refractoriness ..... 724(E), 762, 766, 771
apheresis
bacterial contamination, automated detection of ..... 477, 1331(E), 1486, 1493
citrate effects during 1165
collection efficiency
and WBC reduction 396
by cell separator 396
effect on bleeding time 977
incentives in donors 736
lack of advantage of ..... 727(E), 756, 857
level of growth factors in ..... 1186(E), 1217
PrP^c release in 61
reticulated platelets after 1234
safety of ..... 727(E), 756, 857, 1165
storage after WBC reduction and gamma radiation 236
Babesia microti transmission from 440
bacterial contamination of ..... 477, 815, 857, 862, 1075(L), 1331(E), 1351, 1356, 1365
blood group activity on 504
contamination in MNCs 117
count
as indicator of underutilization of transfusion ..... 577(E), 587
in G–CSF-stimulated granulocyte collection 390
in various methods of preparation 1379
counting with CD61 MoAb and decrease use of platelets 1212
-derived growth factor ..... 1186(E), 1217

donation, apheresis vs. platelet concentrate ..... 727(E), 756, 857, 1331(E)
ganglioside expression on 504
growth factor therapy ..... 1186(E), 1217
HLA alloimmunization to and refractoriness ..... 724(E), 762, 766, 771, 1147
hypotensive reactions after transfusion of 136
identification of donor's platelets in recipients after transfusion 1531
increase in number of after ABO mismatch in heart surgery 790
increment after transfusion ..... 724(E), 762, 766, 771, 917
microvesiculation 243
measuring residual in plasma 87
Mpl, receptor for TPO on 517
pooled, buffy coat-derived, and filtered for WBC reduction 243, 917
prediction of use in neonates 803
price and use of 1617
receptor for TPO 517
refractoriness
assays for detection of ..... 1147, 1626(L)
false, because of Campath chemotherapy ..... 1626(L)
incidence and prevention of ..... 691, 724(E), 762, 766, 771, 1190(E), 1306, 1310
resting 723
reticulated after donation 1234
-rich plasma and yield of platelet growth factor levels ..... 1186(E), 1217
-secreted mediators in HPCs 1431
septic reaction risk after ..... 857, 1075(L), 1331(E), 1351, 1356, 1365, 1486, 1493
standardized apheresis collection of WBC-reduced platelets with RBCs and plasma 1159
storage
after gamma radiation 236
agitation during 809
β-thromboglobuin release 61
in additive solution 917
lesion 236, 243
PrP^c release 61
underutilization of transfusion of ..... 577(E), 587
uptake of plasma TPO by after transfusion 517
WBC reduction
collection efficiency of cell separators 396
failure rate 1030
filter that does not also remove platelets 534
practical experience at multiple sites 1030
process control 102
universal ..... 243, 691, 1030, 1190(E), 1306, 1310, 1591
Plasmodium falciparum transmission to airport mechanic ..... 301(L)
PMNs
activation by Hb-based oxygen carriers 226
cataracts in donors of 1464
Pneumatic pressure device and RBC transfusion 799
Poland, HCV testing of donors ..... 304(L)
Population screening for microchimerism 39
Portugal, HCV testing of donors ..... 848(L)
Postoperative use of desmopressin and tranexamic acid 1285
Posttransfusion purpura, secondary to anti-HPA-5a 633
Pr series 488
Practice guidelines for prenatal and perinatal immunohematology 1446
Prediction rule 1193
Pregnancy, autoantibody development in 1559
Premarital blood tests as incentive for blood donation 736
Prenatal diagnosis of disease, noninvasive 1524
Prenatal immunohematology practice guidelines 1445
Preoperative autologous blood donation ..... 79, 1459(E), 1539
Pressure, external, use of in RBC transfusion 799
Price of platelets and use of for transfusion 1617
Prion protein (PrP^c)
assay for ..... 433(E), 441, 1453(L)
infectivity vs. disease transmission ..... 433(E), 441, 1453(L)
in diagnosis of CJD 1509
in plasma and WBCs ..... 433(E), 441, 1453(L)
introduction by slaughter method of cattle 1325
release in platelet storage ..... 61, 433(E), 441, 1453(L)
Process control WBC-reduced blood components 102
Progeny cells with CD34+ phenotype, engraftment potential 213
Proprionibacterium acnes 477, 815, 862, 1126
Protein C deficiency in cord blood donor at follow-up ..... 606, 1445(L)
Proteus mirabilis 862
Protocols, selective and errors in 713
Providencia rettgeri 1493
PrP^c, see prion protein
PSA screening as donation incentive 736
P-selectin (CD62P)
expression and efficiency of WBC-reduction filters ..... 300(L)
Pseudomonas aeruginosa ..... 477, 862, 1331(E)
Pseudomonas alcaligenes 862
Public perception of risk of transfusion ..... 1326(E), 1329(E), 1335, 1341, 1459(E), 1539
Pulsed-field gel electrophoresis, typing of nosocomial pathogens ..... 1075(L), 1486, 1493

Q

Quality assurance and AABB standards 964
QC
flow cytometric measurement of
residual cells in plasma 87
WBCs after WBC reduction 93, 102
in implementation of blood irradiation program at cancer center 1610
Quality improvement
in transfusion medicine 964, 1204
of transfusion monitoring ..... 577(E), 587

R

Randomized controlled trials and WBC reduction 691
RANTES and Fy phenotype 378
Rat model to study prophylactic transfusion and isovolemic hemorrhage 950, 1515
Ratio of anticoagulant to whole blood in autologous blood donation 1606
RBC(s)
additive solutions for storage of after thawing 923, 928, 933
antibodies after solid organ transplant 365
antigen matching to prevent stroke in sickle cell disease patients 1086
apheresis
effect on bleeding time 977
frozen and thawed 923, 928, 933
autoantibodies 18
automation of freezing and thawing with closed system 923, 928, 933
bacterial contamination in 1126, 1486, 1493
Clostridium perfringens in ..... 427(L), 477
collection of 2 units by apheresis 602, 977, 1373
duration of mechanical ventilation after transfusion of 885
experimental additive solutions for 11-week storage 1586
fatal reaction due to *Staphylococcus epidermidis* in 1493
frozen 401, 540, 550, 923, 928, 933
immunologic changes in conversion of group A cells to group O 908
labels for survival studies of ..... 933, 1072(L)
loss during WBC reduction 794
measuring residual in plasma 87
modification of wash solutions in automated deglycerolization 923, 928, 933

microvesiculation 1586
oxygen reserve and transfusion of 2,3 DPG- depleted RBCs 950, 1515
PEG-modified 1225
production after preoperative autologous donation ..... 179, 1459(E), 1539
rophylactic transfusion and oxygen reserve in isovolemic rats 950, 1515
recovery
after freezing, thawing, and irradiation 540
after outdate, rejuvenation, and freezing 550
after storage for 11 weeks in experimental additive solution 1586
of apheresis RBCs after freezing and thawing 923 928, 933
variations in, using various labels for determination of ..... 933, 1072(L)
rosetting ..... 163, 908, 1073(L)
salvage by rejuvenation and freezing of outdated AS-1 RBCs 550
standardized apheresis collection of WBC-reduced RBCs with plasma and platelets 1159
storage
additive solutions for after thawing 923, 928, 933
and hemolysis when transfused with external pressure device 799
Fas and Fas ligand in ..... 316(E), 416, 988
fluctuations in frozen temperature 401
for 11 weeks 1586
IL-1 receptor antagonist in 67
in diethylenetriaminopentaacetic acid in 556
in experimental additive solutions 1045
quality in, as determined by various labels for RBC survival studies ..... 933, 1072(L)
refrigeration and lack of transmission of syphilis ..... 744, 976(E), 1069
soluble HLA class I molecules in ..... 316(E), 416, 988
WBC degranulation in 691
substitutes
bovine Hb-based oxygen carrier used in dogs 219
bovine Hb-based oxygen carrier used in hamster window model 1290
Hb-based oxygen carriers 226, 287
progress in development of 287
survival
after freezing, thawing, and irradiation 540
after storage for 11 weeks in experimental additive solution 1586
in autoimmune hemolytic anemia 493
of apheresis RBCs after freezing and thawing 923, 928, 933
of autologous RBCs with various radioactive labels ..... 933, 1072(L)
of incompatible RBCs in patient with alloanti-Kp^b 611
of outdated, rejuvenated, and frozen RBCs 550
transfusion
and postoperative mechanical ventilation in coronary artery bypass graft surgery 885
billing data, validity of ..... 437(E), 530
effect of EPO use in neonates 406
incompatible 611
increased number of after ABO-mismatched platelet transfusion in heart surgery 790
in patients with sickle cell disease in Jamaica 596
increased need for in anemic patients because of loss of RBCs during WBC reduction 794
iron overload in patients with AML 818
number of and storage time of in duration of mechanical ventilation after surgery 885
of antigen-matched RBCs in sickle cell disease 1086
of autologous whole blood or RBCs and FFP 470/851, 988
of 2,3 DPG-depleted RBCs in rats 950, 1515
of stored vs. fresh RBCs in rats 1515
predicting need for in coronary artery bypass graft surgery 1193
septic reaction risk after ..... 857, 1331(E), 1351, 1356, 1365, 1486, 1493
underutilitzation of ..... 577(E), 587
use of external pressure device in 799
Virus inactivation in 1154
WBC reduction
and incidence of transfusion reactions 997
conditions that affect efficacy of 540
counting WBCs after 93, 102
failure rate 1030
IL-1 receptor antagonist in 67
loss of RBCs in and increased need for transfusion in anemic patients 794
practical experience in multiple centers 1030
process control of 102
universal vs. selected bedside and reactions 997
Recommendations for universal WBC reduction ..... 1190(E), 1306, 1310
Recovery of
frozen, thawed, and irradiated RBCs 540
apheresis RBCs 923, 928, 933
outdated, rejuvenated, and frozen RBCs 550
Recruitment/retention of blood donors ..... 165(E), 172, 360/721, 736, 1179, 1181, 1185, 1326(E), 1329(E), 1335, 1341
Refractoriness to platelet transfusion
assays to detect WBC antibodies in ..... 1147, 1626(L)
false, because of Campath chemotherapy ..... 1626(L)
prevention by WBC reduction ..... 691, 1190(E), 1306, 1310
Regulation of topical wound-healing products ..... 1186(E), 1217
Rejuvenation and freezing of outdated AS-1 RBCs 550
Religion and refusal of transfusion ..... 577(E), 587
Renal insufficiency in neonates as predictor of need for platelet transfusion 803
Repertoire cloning ..... 1(E), 6
Reporting of
bacterial contamination 1486, 1493
errors in blood banking ..... 575(E), 581, 1204
Requirements for manuscript submission 157
Respiratory burst, neutrophil, effect of resuscitation fluids on 1064
Resuscitation fluids, effect on neutrophil respiratory burst 1064
Retesting donors of FFP for viral markers ..... 1172(L)
Reticulated platelets 1234
Reticulocytopenia during hyperhemolysis 323
Rh blood group system
antibody after HPC transplant 106
antigen matching of RBCs for patients with sickle cell disease 1086
Dal, partial D phenotype ..... 971(L)
DBS, partial D phenotype 1052
D^c, partial c phenotype 1136
E variants in Japanese 1408
MAR (RH51) 53
microplate agglutination method for testing 627
molecular classification of weak D 45
paraben-dependent antibody to protein in 371
structure and expression of C 24
weak D types in Central Europe 45
RHD-RhcE(5)-RHD hybrid allele 1052
Rh immune globulin, labeling D+ cells after receipt of 1059
Risk factors for syphilis after false-positive screening test 744
Risk
of plateletpheresis ..... 727(E), 756, 857, 1165
of septic transfusion reaction ..... 862, 857, 1075(L), 1331(E), 1351, 1356, 1365, 1486, 1493
of travel to donate autologous blood ..... 152(L)
perception ..... 1326(E), 1329(E), 1335, 1341, 1459(E), 1539
transfusion ..... 1326(E), 1329(E), 1335, 1341, 1486, 1493
Ristocetin cofactor activity ..... 4(E), 56, 151(L), 153(L)

Robertson, Lawrence Bruce 283
Robotics 483
Rubella, cold agglutinin disease after 488

S

Safety of
apheresis donation of
2 units of RBCs 602, 923, 928, 933
platelets ..... 727(E), 756, 857, 1165, 1234
blood donation ..... 309(E), 353, 390, 1234, 1475
blood supply ..... 165(E), 172, 716(L), 736, 1081(E), 1093, 1107/1632, 1249, 1172(L), 1326(E), 1329(E), 1335, 1341, 1459(E), 1469, 1539
Hb-based oxygen carriers 219, 226, 287
Sample, timing of for detection of bacteria in blood 815
Scrub typhus, transfusion transmission ..... 1454(L)
SE (FUT2) 31, 1279
Sepsis and transfusion ..... 74, 287, 427(L), 477, 691, 815, 857, 862, 898, 1075(L), 1426
SD plasma, parvovirus B19 antibodies in 130
Serratia liquefaciens ..... 862, 1331(E), 1357, 1365, 1493
Serratia marcescens ..... 477, 1331(E), 1357, 1493
Serum, concentration of cell-free genomic DNA in 276
Serum-free medium, expansion of cord blood cells ..... 718(L), 1567
Serum repository, HBV DNA testing of 878
Sexually transmitted diseases in Norwegian blood donors 1480
Shiga toxin 898
Shigella dysenteriae 898
Sickle cell disease
filtration WBC reduction of blood from donors with 1192
hyperhemolysis in 323
management of patients with in Jamaica 596
modeling of erythrocytapheresis 257
phenotype matching to prevent stroke in 1086
Sickle cell trait, filtration WBC reduction of blood from donors with 1192
Single-stranded conformational polymorphism PCR 1531
Skin preparation before donation ..... 427(L), 477, 815, 1075(L), 857, 1331(E), 1351, 1356, 1365
Slaughter of cattle, dissemination of brain tissue in 1325
Software packages
and process control 102
and treatment of sickle cell disease 256
Sodium bicarbonate 1045
Sodium chloride 1045
Solid organ transplantation ..... 365, 419, 437(E), 522
Solid-phase RBC adherence assay 621
Spleen enlargement/rupture after G–CSF ..... 168(E), 184
Spleen, release of platelets from after donation 1234
Standard operating procedures, compliance with ..... 575(E), 581
Standardization of transfusion protocols in USA 713
Standardization of topical wound-healing products ..... 1186(E), 1217
Standardized, concurrent collection of WBC-reduced RBCs, platelets, and plasma by apheresis 159
Staphylococcal protein A column 136
Staphylococcus aureus ..... 477, 862, 1331(E), 477, 815, 857, 1331(E), 1351, 1356, 1365
Staphylococcus aureus, methicillin-resistant 1426, 1493
Staphylococcus capitis 1126
Staphylococcus epidermidis ..... 477, 815, 862, 1075(L), 1493
Staphylococcus hominis 862
Staphylococcus lugdenesis 1493
Staphylococcus saprophyticus 1493
Staphylococcus warneri 862
Stem cell collection filter 1014
Stem cell factor ..... 168(E), 206, 659, 1431, 1438, 1567
Steroid and G–CSF use in granulocyte collection, cataracts in donors 1464
Streptococcus, group G 1493
Streptococcus agalactiae 1493
Streptococcus mitis 862
Streptococcus pneumoniae 1493
Streptococcus pyrogenes 477
Streptococcus salivarius 862
Streptococcus vestibularis 862
Streptococcus viridans 477
Stroke prevention in sickle cell disease 1086
Surgery, desmopressin and tranexamic acid in 1285
Surgery, use of preoperative autologous blood donation in ..... 1459(E), 1539
Superoxide anion production 1064
Superoxide dismutase reactivity in nucleic acid testing for HCV RNA ..... 1625(L)
Survival of
frozen, thawed,
apheresis RBCs 923, 928, 933
irradiated RBCs 540
incompatible RBCs in patient with anti-Kp^b 611
outdated, rejuvenated, and frozen RBCs 550
RBCs in hemolytic anemia 493
Swedish transfusion recipients ..... 251, 1173(L)
Swirling detection of bacteria ..... 477, 815, 857, 1331(E), 1351, 1356, 1365
Syphilis
risk factors for after false-positive test in screening 744
screening
of babies 6 months after cord blood donation ..... 606, 1445(L)
in past and today ..... 744, 976(E), 1069
Systemic lupus erythematosus 276, 462

T

Taiwanese, Secretor gene in 1279
T-cell
collection with separator 940, 1577
depletion from HPCs 783, 1577
receptor 687
Temperature
donor's, effect of hot or cold beverage and chewing gum 1241
effect on filtration WBC reduction of RBCs 540
fluctuations and frozen RBC storage 401
Thrombocytopenia
counting platelets in with CD61 MoAb 1212
in donors ..... 727(E), 756, 857
indicator of underutilization of transfusion ..... 577(E), 587
Thrombosis and tranexamic acid 1285
Thrombotic thrombocytopenic purpura ..... 570(L), 840, 1212
Thrombopoietin, see TPO
Thromboxane B_2 977
Time from work as donor incentive ..... 165(E), 172, 736
Timing of
preoperative autologous blood donation to replace RBCs by erythropoiesis ..... 1459(E), 1539
filtration WBC reduction of RBCs and efficacy 540
sample collection for detection of bacteria 815
WBC-reduction filtration ..... 300(L), 540
Tissue oxygenation by bovine cell-free Hb solution in hamster window model 1290
Tissue oxygenation in rat after transfusion of stored or fresh RBCs 1515
TNFα levels
after transfusion of autologous whole blood or RBCs and FFP 470/851, 988
in conversion of group A RBCs to group O 908
in TRALI ..... 312(E), 317
Tolerance and transplanted organ, tissue, or cells 419
Topical wound healing ..... 1186(E), 1217
Toxicity of G–CSF regimens 1030
TPO ..... 168(E), 206, 517, 803, 1567
Traffic accident risk and autologous blood donation ..... 152(L)
TRALI, see transfusion-related acute lung injury
Tranexamic acid 1285
Transgenic mice production of MoAbs 1393
Transforming growth factor β ..... 1186(E), 1217

Transfusion
and
development of autoimmune disorders ... 462
immune modulation ... 67, 106, 154(L), 316(E), 416, 462, 470/851, 691, 988
immune response ... 106, 154(L), 462, 470/851, 988
inflammatory response ... 885
metastasis and tumor dissemination ... 462
-associated GVHD
and solid organ transplantation ... 419
prevention by
gamma radiation of apheresis platelets ... 236
irradiation of frozen and thawed RBCs ... 540
treatment with extracorporeal photochemotherapy in children ... 1299
autologous and immune modulation ... 470/851, 988
billing accuracy for ... 437(E), 522, 530
costs
and safety ... 713, 716(L), 1081(E), 1093, 1107/1632, 1249, 1459(E), 1539
by diagnosis-related group ... 437(E), 522, 530
of medical interventions triggered by HCV lookback ... 832
development of microchimerism after ... 276
errors and accidents in ... 575(E), 581, 713, 964, 1204
first photograph of ... 968
indication for and risk of septic reaction ... 862, 1331(E), 1351, 1356, 1365, 1486, 1493
long-term survival after in Sweden ... 251, 1173(L)
medicine, history of in Canada ... 283
parvovirus B19 transmission ... 130
practice
accidents and errors in ... 713, 964, 1204
accurate platelet count with CD61 MoAb and decrease in platelet transfusion ... 1212
ABO-mismatched platelet transfusion in heart surgery ... 790
and new infectious agents ... 1114
and postoperative duration of mechanical ventilation ... 885
antigen-matched RBCs for patients with sickle cell disease ... 1086
apheresis platelets to decrease septic transfusion reactions ... 857, 1075(L), 1331(E),
billing data validation ... 437(E), 530
blood-sparing in total knee surgery ... 1285
EPO and iron supplementation in orthopedic surgery ... 957
evaluation of cost ... 473(E), 522, 713, 716(L)
for various blood services and Diagnosis-Related Groups ... 437(E), 522
group O FFP ... 4(E), 56
impact of RBC substitutes on ... 287
implementation of irradiation program ... 1610
in coronary artery bypass graft surgery ... 591, 977, 1193
in children with ALL ... 873
in HLA-alloimmunized patients ... 724(E), 762, 766, 771
in incompatible crossmatch ... 611
in patients with sickle cell disease in Jamaica ... 596
in nonsurgical blood loss ... 977
PEG-modified RBCs ... 1225
preferential use of MB-treated products ... 1548
prevention of iron overload in AML patients ... 828
price and use of platelets in ... 1617
prophylactic transfusion and oxygen reserve in isovolemic rats ... 950, 1515
selective protocols and errors ... 713
sharing information on errors and accidents ... 964, 1204
underutilization of ... 577(E), 587
universal WBC reduction ... 1030, 1190(E), 1306, 1310
use of EPO and iron supplementation in orthopedic surgery ... 957
use of donor retested FFP ... 1172(L)
use of preoperative autologous blood donation ... 1459(E), 1539
WBC reduction and ALL outcome in children ... 873
WBC reduction, loss of RBCs, and increased RBC transfusion in HIV+ anemic patients ... 794
reactions
bacteria in platelets ... 857
drug-dependent ... 893
hyperhemolysis in sickle cell disease ... 323
hypotensive and bradykinin metabolism ... 136
transfusion-related acute lung injury (TRALI)
after IVIG ... 264
and plasma from multiparous donors ... 312(E), 317
due to HLA class II antibodies ... 1244
recurrent ... 1421
septic ... 74, 287, 427(L), 477, 815, 857, 862, 898, 1075(L), 1126, 1331(E), 1351, 1356, 1365, 1486, 1493
WBC reduction and ... 691, 997
risk of transmission of infectious agents or bacteria ... 251, 1173(L), 1326(E), 1329(E), 1331(E), 1335, 1341, 1351, 1356, 1365, 1486, 1493
refusal ... 577(E), 587
reporting errors in ... 575(E), 577(E), 587, 581, 713, 716(L), 964, 1204, 1331(E), 1351, 1356, 1365, 1486, 1493
safety ... 713, 716(L), 964, 1081(E), 1093, 1107/1632, 1249, 1172(L), 1204, 1331(E), 1351, 1356, 1365, 1459(E), 1469, 1539, 1486, 1493
service, centralization of ... 713
transmission of
Babesia microti ... 440
CJD ... 61, 433(E), 441, 449/1079, 1325, 1453(L), 1509
CMV ... 560
HBV ... 338, 878, 1074(L) 1081(E), 1093, 1107/1632, 1249
HCV ... 304(L), 308, 333, 338, 427(L), 428(L), 832, 1625(L)
human herpes virus 8 ... 1120
malaria ... 301(L)
scrub typhus ... 1454(L)
syphilis ... 744, 976(E), 1069
West Nile virus ... 1320(L)
trigger in cardiac bypass graft surgery ... 591
underutilization of ... 577(E), 578
universal WBC reduction ... 1030, 1190(E), 1306, 1310
via external pressure device ... 799
Transfusion Medicine Illustrated ... 164(E), 440, 723, 975, 1073(L), 1192, 1463
Transmissible spongiform encephalopathies ... 61, 433(E), 441, 1325, 1453(L), 1509

Transplantation
costs of ... 437(E), 522, 530
dendritic cells ... 117, 853(E), 940
HPCs
ABO-incompatible ... 106
adoptive immunotherapy ... 853(E)
and allograft tolerance ... 419
and microchimerism ... 39, 419
antibody development after ... 106
CD34+ cell selection in ... 783, 940, 1008
comparison of cell separators for collection of ... 1562
CMV disease after ... 783
collection, chemotherapy regimens, and growth factor combinations in ... 168(E), 190, 196, 674, 681
cryopreservation ... 579(E), 667
detection of bcr/*abl* cells in ... 111
erythrophagocytosis and ABO-mismatched ... 1463
donor safety ... 168(E), 184, 201
expansion ... 456, 579(E), 659, 667, 718(L), 853(E), 1567
G–CSF administration
schedule ... 168(E), 190
to children ... 168(E), 201

gene therapy ... 853(E)
GVHD in ... 419, 1299
immune reconstitution after ... 783
in patients with
breast cancer ... 168(E), 206, 1577
germ cell tumor ... 168(E), 196
multiple myeloma ... 168(E), 206
ovarian cancer ... 1577
repeat mobilization and collection of ... 1438
platelet-secreted mediators in ... 1431
storage in –80°C mechanical freezer before ... 579(E), 667
T-cell depletion in ... 783
use of amifostine in ... 168(E), 196
neutropenia in and granulocyte transfusion ... 390
solid organ
antibody development after ... 365
donor cell transfusions and tolerance in ... 419
GVHD in ... 419
microchimerism in ... 365, 419
umbilical cord blood ... 213, 302(L), 344, 599(E), 606, 667, 1014, 1445(L)
Treatment of GVHD with extracorporeal photochemotherapy ... 1299
Treponema pallidum ... 744, 976(E), 1069
TT virus
genotyping in
Chinese ... 1001
Japanese hemophilia patients, patients with chronic HCV infection, and healthy subjects ... 1130
inactivation ... 382
lack of transmission by immunoglobulins ... 1505
Tube agglutination DAT ... 1258
Turning away donors after emergency ... 1179, 1181, 1185

U

Umbilical cord blood
and gestational age ... 302(L)
as source of HPCs ... 853(E)
CD34+ cell selection with stem cell collection filter ... 1014
cell expansion ... 213, 718(L), 1567
cryopreservation ... 579(E), 667
dextran sedimentation of ... 344, 1014
progeny ... 213
RBC removal ... 1014
screening babies for viral markers and history 6 months after cord blood donation ... 606, 1445(L)
volume reduction of ... 344, 1014
Underutilization of transfusion ... 577(E), 587
Universal WBC reduction ... 243, 560, 691, 713, 716(L), 997, 1190(E), 1306, 1310
University blood service use by Diagnosis Related Group ... 437(E), 522
University HealthSystem Consortium ... 1190(E), 1306, 1310
Unreported deferrable risk and anonymous questionnaire on high-risk sexual habits ... 1480
donation incentives ... 736
Urinary malformation in cord blood donor at follow-up ... 606, 1445(L)
Urine dipstick detection of bacteria in blood components ... 477, 815, 857, 1331(E), 1351, 1356, 1365, 1486, 1493
Urokinase ... 1384
UVC radiation and inactivation of parvovirus B19 ... 456

V

Validation of
billing records for RBC transfusion ... 437(E), 530
methods for use in QC ... 87, 93, 102
Valve replacement surgery, ABO-mismatched platelet transfusions in ... 790
Variant CJD ... 61, 433(E), 441, 449/1079, 1325, 1453(L), 1509
Vascular cell adhesion molecule-1 ... 168(E), 206, 323
Vasovagal syncopal reactions after blood donation and injuries from ... 1475
Venipuncture and nerve injury after whole-blood donation ... 571(L)
Ventilation, mechanical duration after surgery and transfusion ... 885
Viral marker screening of mother and baby 6 months after cord blood donation ... 606, 1445(L)
Virus activation by WBCs ... 691
Virus inactivation
assessment of ... 456
pasteurization ... 382
in plasma ... 82, 151(L), 382, 1548
of duck hepatitis B by dimethylmethylene blue in RBCs ... 1154
of parvovirus B19 ... 456
of TT virus ... 382
removal/effect on PrP^{sc} ... 433(E), 441, 449/1079, 1453(L)
Virus infection rates in repeat donors ... 730
Virus transmission
and universal WBC reduction ... 1190(E), 1306, 1310
by plasma products, assessment of causality ... 1020
Volunteer blood donation ... 165(E), 172, 730
vWD ... 4(E), 56
vWF levels
and ABO blood group ... 4(E), 56
in FVIII concentrates ... 153(L)
in pathogenesis of thrombotic thrombocytopenic purpura ... 840
in plasma after
MB treatment ... 151(L), 1548
virus inactivation and filtration WBC reduction ... 82

W

Wall, transfusion safety ... 716(L)
Warm autoimmune hemolytic anemia ... 13, 18, 493, 1073(L)
Waste of preoperative autologous blood ... 1459(E), 1539
WBC
activation
and WBC-reduction filter efficiency ... 300(L)
by Hb-based oxygen carriers ... 226, 287
of viruses ... 691
adhesion molecules and WBC reduction ... 717(L)
antibodies, assays to detect ... 1147
apostosis in stored RBCs ... 67, 462, 691
clearance in mice ... 637
contamination in platelet components for preparation of topical wound-healing products ... 1186(E), 1217
count in G–CSF-stimulated collection of granulocytes ... 390
count in platelet preparations ... 1379
damage and leakage of granular contents during RBC storage ... 691
expression of CTLA-4 epitopes on after storage in RBCs ... 462
reduction
adhesion molecules and ... 717(L)
and concurrent, standardized collection of RBCs, plasma, and platelets ... 1159
and immune modulation ... 691, 873
and infection ... 691
and outcome in children with ALL ... 873
and refractoriness to platelet transfusion ... 691, 1147, 1190(E), 1306, 1310
as example of selective transfusion protocol ... 713
cell separator collection efficiency ... 396
CMV transmission and ... 560, 691, 1190(E), 1306, 1310
conditions that affect efficiency ... 300(L), 540
counting WBCs after ... 93
decrease in transfusion reactions ... 691, 1190(E), 1306, 1310
effect on bacteria ... 691
elimination of CMV serology tests ... 560
evidence-based recommendation for ... 1190(E), 1306, 1310

extreme in apheresis platelets 236
failure rate 1030
filters
adhesion molecules and ..... 717(L)
and hypotensive transfusion reactions 136
clogging by sickle cells 1192
conditions that affect efficacy in RBCs 540
in-line and RBC apheresis 1373
that do not remove platelets 534
filtration efficiency ..... 300(L), 540
HLA antibodies and 691
HL60 cells in study of ..... 717(L)
in apheresis platelets and storage after gamma radiation 236
in RBCs and immune modulation 67, 462, 691, 873
in RBCs by glycerolization and deglycerolization with/without freezing 923, 928, 933
loss of RBCs during and increased need for transfusion in anemic patients with HIV 794
lymphocyte subsets after 1591
mechanisms in ..... 300(L), 717(L)
of blood from patients with sickle cell disease or trait 1192
of plasma after virus inactivation 82
pooled, buffy coat-derived platelets 243
practical experience with and variation among sites 1030
process control of 102
recommendations for use of ..... 1190(E), 1306, 1310
removal of *Chlamydia pneumoniae* 1114
standards for 1030
timing of ..... 300(L), 540
universal ..... 243, 560, 691, 713, 1030, 1190(E), 1306, 1310
release of soluble HLA class I molecules, Fas, and Fas ligand during storage of ..... 316(E), 416, 988
subsets that remain after WBC reduction 1591
West Nile virus antibodies in donors in France ..... 1320(L)
Wettability of WBC-reduction filters and efficacy of WBC removal 540
Whole blood
anticoagulant concentration on collection of 1606
autologous or RBC and FFP transfusion 470/851, 988
collection to reduce bacterial contamination ..... 74, 427(L), 815, 1486, 1493
donation, venous nerve injuries after ..... 571(L)
effect of storage on donor WBC clearance in mice 637
generation of reticulated platelets after donation of 1234
incentives in repeat donors of 736
incidence rates of virus infections in repeat and community donors of 730
single unit or mini-pool nucleic acid testing of ..... 483, 643, 845(L) 1081(E), 1093, 1107/1632, 1249
WBC reduction without removal of platelets from 534
Wound healing, topical growth factor ..... 1186(E), 1217

X

Xenogeneic transfusion, donor WBC clearance in mice 637

Y

Yersinia enterocolitica ..... 477, 815, 857, 1331(E), 1351, 1356, 1365, 1486, 1493